ALK and non-small cell lung carcinoma: In the ATLANTIC34 study with durvalumab (third‐line or more advanced NSCLC), ORR, PFS, and OS were better in a patient with high expression of PD‐L1 than those with a low expression of PD‐L1, and those with EGFR-/ALK- were better than those with EGFR+/ALK+.